Extra Holiday Pay
Are you entitled?
Page 25

Whistleblowing
Making it count
Pages 7, 21 & 25

PDA Challenges
NHS Maternity Policy
Page 4

Decriminalisation
Concerns for Hospital Pharmacists
Page 4

Thistle Hospital Insurance scheme closed

To strike off or not to strike off?

Capping numbers of pharmacy graduates

Boots lose court case
The proposals to prevent criminal sanctions for dispensing errors represent progress, but they fail the ‘Elizabeth Lee’ test and exclude many hospital pharmacists.

Since 2009, when pharmacist Elizabeth Lee received a suspended prison sentence for making a dispensing error the profession has been awaiting a change in the law.

It is clear to me that the necessary changes were never going to be easy to make because those who had lost their loved one to the effects of a dispensing error often took the view (unsurprisingly) that a criminal sanction for a dispensing error is a powerful incentive for pharmacists not to make such errors. This logic has considerable traction with MPs and it offers a sobering objection to those seeking decriminalisation.

Eventually, the greatest impetus for change came from the Francis Inquiry which considered hospital practice and placed great emphasis upon the Duty of Candour and the need for all healthcare professionals to report mistakes. It clarified that a learning culture enabling mistakes to be used as a learning exercise offers much better protection to members of the public than does the threat of criminal prosecution.

The current risk of prosecution has the effect of suppressing reporting in pharmacy, consequently, this Francis recommendation was the trump card that the profession desperately needed.

For nearly two years the Rebalancing Medicines Legislation Consultation and Pharmacy Regulation Programme Board has been preparing its proposals and the result has been released in the form of a consultation.

Any progress that can be made is to be welcomed and the programme board deserves credit for that, but we are concerned that the proposals do not go far enough to remove the risk of prosecution.

The proposals as such, don’t remove the threat of prosecution, but they do provide a legal defence for pharmacists, similar to the ‘Elizabeth Lee’ test (Section 85.5).

The defences proposed, had they been available in 2009 would not have helped her in preventing her prosecution under Section 85.5, even though she could satisfy all of the conditions. Consequently, these consultation proposals do not only fail many hospital pharmacists, they also fail the ‘Elizabeth Lee test’.

Additionally, they do not offer protection from other sources of statutory offences found in the Human Medicines Regulations.

Disappointingly, as they stand, they do not represent a step in progress proposal as they do not lift the spectre of criminal prosecutions for pharmacists.

As is described on pages 4 and 5 of this magazine, the PDA is now engaged with senior Counsel on a comprehensive study of the proposals so as to prepare a detailed response to the consultation.

It will be our intention to press for changes that may yet provide a more comprehensive solution. Members will be provided with the full analysis once this is completed.

Thistle Hospital Pharmacists PI insurance scheme to close

When hospital pharmacists were recognised that they were personally exposed to medical malpractice claims back in the 1970’s, there were at that time no individual pharmacist PI insurance providers.

The then Pharmaceutical Society of Great Britain established a Professional indemnity insurance scheme was established. Today, a number of hospital pharmacists who are not registered, initially, we were led to believe that a solution would be found that could be offered to the entire profession; there appears to be a change of heart.

We are being told that protection for hospital pharmacists will come later but this is not acceptable. We have formally written to the Board to ask that it redoubles its efforts to give us an all-embracing proposal.

The other major disappointment is that the defences are limited only to a prosecution under Sections 63 and 64 of the Medicines Act involving the preparation and supply of medicines.

When we met with the programme board chairman, we asked him not restrict his efforts but to include a range of other potential prosecutions, like the labelling offences for which pharmacist Elizabeth Lee was prosecuted (Section 85.5). The defences being proposed, had they been available in 2009 would not have helped her in preventing her prosecution under Section 85.5, even though she could satisfy all of the conditions. Consequently, these consultation proposals do not only fail many hospital pharmacists, they also fail the ‘Elizabeth Lee test’.

It will be our intention to press for changes that may yet provide a more comprehensive solution. Members will be provided with the full analysis once this is completed.

Thistle Hospital Pharmacists PI insurance scheme to close

When hospital pharmacists were recognised that they were personally exposed to medical malpractice claims back in the 1970’s, there were at that time no individual pharmacist PI insurance providers. The then Pharmaceutical Society of Great Britain established a Professional indemnity insurance scheme was established. Today, a number of hospital pharmacists who are not registered, initially, we were led to believe that a solution would be found that could be offered to the entire profession; there appears to be a change of heart.

We are being told that protection for hospital pharmacists will come later but this is not acceptable. We have formally written to the Board to ask that it redoubles its efforts to give us an all-embracing proposal.

The other major disappointment is that the defences are limited only to a prosecution under Sections 63 and 64 of the Medicines Act involving the preparation and supply of medicines.

When we met with the programme board chairman, we asked him not restrict his efforts but to include a range of other potential prosecutions, like the labelling offences for which pharmacist Elizabeth Lee was prosecuted (Section 85.5). The defences being proposed, had they been available in 2009 would not have helped her in preventing her prosecution under Section 85.5, even though she could satisfy all of the conditions. Consequently, these consultation proposals do not only fail many hospital pharmacists, they also fail the ‘Elizabeth Lee test’.

It will be our intention to press for changes that may yet provide a more comprehensive solution. Members will be provided with the full analysis once this is completed.

Thistle Hospital Pharmacists PI insurance scheme to close

When hospital pharmacists were recognised that they were personally exposed to medical malpractice claims back in the 1970’s, there were at that time no individual pharmacist PI insurance providers. The then Pharmaceutical Society of Great Britain established a Professional indemnity insurance scheme was established. Today, a number of hospital pharmacists who are not registered, initially, we were led to believe that a solution would be found that could be offered to the entire profession; there appears to be a change of heart.

We are being told that protection for hospital pharmacists will come later but this is not acceptable. We have formally written to the Board to ask that it redoubles its efforts to give us an all-embracing proposal.

The other major disappointment is that the defences are limited only to a prosecution under Sections 63 and 64 of the Medicines Act involving the preparation and supply of medicines.

When we met with the programme board chairman, we asked him not restrict his efforts but to include a range of other potential prosecutions, like the labelling offences for which pharmacist Elizabeth Lee was prosecuted (Section 85.5). The defences being proposed, had they been available in 2009 would not have helped her in preventing her prosecution under Section 85.5, even though she could satisfy all of the conditions. Consequently, these consultation proposals do not only fail many hospital pharmacists, they also fail the ‘Elizabeth Lee test’.

It will be our intention to press for changes that may yet provide a more comprehensive solution. Members will be provided with the full analysis once this is completed.
Government proposals on decriminalisation of dispensing errors released for consultation

Many pharmacists will recall the shock they felt when pharmacist Elizabeth Lee was given a suspended prison sentence for making a dispensing error. Ultimately, the PDA was able to successfully overturn this judgement in the Royal Court of Appeal in 2009.

The PDA’s case succeeded because it managed to secure a new and favourable interpretation of Section 85.5 of the Medicines Act which meant that from that day on, only those pharmacists who owned a pharmacy business could be prosecuted for applying the wrong label onto dispensed medicines. Since most pharmacists are employees or locums, this took more than 80% of all pharmacists out of the firing line in relation to that offence.

It still left pharmacists exposed to prosecutions from other sections of the Act (such as Section 64) which covered the dispensing of the wrong substance. Because of that, since the Elizabeth Lee case, the profession has been eagerly awaiting a change in the law.

There has never been a question of pharmacists trying to avoid the consequences of their actions. If any pharmacists act in a way that is reckless or grossly negligent, then there is agreement within the profession that they should face the full consequences of the criminal law. Provisions in the law already exist to accomplish this. Where it becomes clear that no gross negligence has occurred, but it is down to a simple human error, then other healthcare professionals are referred to their regulator. However currently, in such situations pharmacists are the only healthcare professional ever exposed to a criminal offence through simply making a dispensing error whether it is damaging to a patient or not.

The effect of this is toxic and not in the patient’s interest, for in the event of a dispensing error, pharmacists may be reluctant to complete an error log. The prospect of criminal prosecution has blighted pharmacy practice and has restricted the good learning that could come from subsequent analysis.

The time when pharmacists are treated in the same way as other healthcare professionals is long overdue, the spectre of criminal sanctions for inadvertent dispensing errors has to be removed.

The journey has been long, frustrating and arduous. For the last six years the government has been trying to secure a change in the law so as to prevent a pharmacist making an inadvertent dispensing error from being prosecuted by the courts. This has not been easy as a change in the law can sometimes lead to unintended consequences.

The government’s first effort was aimed at the Crown Prosecution Service and an attempt was made to establish an arrangement with the CPS, where the police, instead of prosecuting pharmacists would leave the job of discipline for dispensing errors to the Pharmacy Regulator. This did not deliver the required results.

The next attempt was a proposal to change the law giving pharmacists a ‘Due Diligence’ Defence. However, the analysis provided by PDA Counsel was that this would have actually made the situation worse as pharmacists who were owners and exposed and asked that his board addressed that outstanding issue. He explained that this would have essentially removed any defence offered by his board, because if it was a section of the Act that was the responsibility of another branch of the government (the MHRA).

The PDA had already explained its position on Section 85.5 at previous meetings with the MHRA, and on the advice of his leading Counsel to establish whether they will provide pharmacists with what they have been waiting for – a meaningful and effective defence to a criminal prosecution in the event that they are involved in the commission of an inadvertent dispensing error.

The PDA had already explained its position on Section 85.5 at previous meetings with the MHRA, and on the advice of his leading Counsel to establish whether they will provide pharmacists with what they have been waiting for – a meaningful and effective defence to a criminal prosecution in the event that they are involved in the commission of an inadvertent dispensing error.

In late 2014 however, it was announced that the MHRA had managed to consolidate section 85.5 of the Act, into the Human Medicines Regulations. The effect of the new wording used now meant that the hard earned interpretation secured in the Elizabeth Lee case was now altogether lost. Currently, all pharmacists are yet again exposed to prosecutions from labelling offences. The PDA has been told that the MHRA would now try and repair the situation and the PDA has asked for a timetable.

In February of 2015, the work of the Rebalancing Committee relating to decriminalisation was released for consultation. That fresh proposals on changes to the law have finally been released is a welcome development. As on previous occasions, the PDA will now be looking objectively at the detail of the proposals and consulting with leading Counsel to establish whether they will provide pharmacists with what they have been waiting for – a meaningful and effective defence to a criminal prosecution in the event that they are involved in the commission of an inadvertent dispensing error.

In a recent case, the PDA Union were made aware that the Maternity Policy for NHS Commissioning Support Units states that bank holiday leave is not accrued whilst on paid or unpaid maternity leave.

This emerged when a PDA member whose entitlement as laid out in the staff handbook was 27 days annual leave and 8 days ‘General Public Holidays’, sought confirmation that her accrual was 36 days, as she understood it to be her contractual right.

When she was told that public holidays were not accrued she challenged her employer with the support of the PDA Union. She argued that she was being treated less favourably than her colleagues were because of her maternity. Her grievance was rejected and in the employer’s opinion the decision was not discriminatory because:

- Bank holidays should be taken as they fall and as other staff take bank holidays as they fall she is not being treated differently.
- The statutory minimum leave requirements for staff, as the Working Time Directive apply in the UK of 28 days (prorate for part-time) does not differentiate between annual leave and public holidays.
- All NHS staff have a minimum of 27 days leave plus public holidays and therefore with the exception of staff who are on maternity leave for the full ‘leave year’ they would potentially have at least one bank holiday in the year therefore lifting them above the statutory minimum of 28 days.
- The employer conceded that she could accrue one of the public holidays which would take her up to the statutory 28 days but would concede no more.

Counsel has advised the PDAU that there are legal precedents to suggest that public holidays should be included in the contractual entitlement to accrue when on maternity leave. And on the issue of taking bank holidays ‘as they fall’, even if the employer is correct, that the member was required to take them at that point, and did so on the prescribed days during her maternity leave, arguably she was treated less favourably by the employer in such circumstances. Whereas those otherwise at work would get the day off the employee was already off work on maternity leave. For each public holiday she either lost a day of maternity leave or a day of leave for the public holiday.

The member lodged a claim in the Employment Tribunal for unlawful deductions of pay and entitlement and sex discrimination, as she has been disadvantaged whilst on maternity leave.

This is a complex case on the intersect of contract law, domestic statute and European directives. The PDAU expect the claim to be defended vigorously as there will be many employees in the NHS and other organisations that may lodge similar claims seeking these 8 days if this is successful.

PDAU Union questions NHS Maternity Policy

The PDA Union is at the centre of a potential claim which could alter the accrued holiday pay for women whilst on Maternity Leave.

“the time when pharmacists are treated in the same way as other healthcare professionals is long overdue”

The £56 million Rebalancing programme board which was convened nearly two years ago following the (Section 85.5) Lee case has now been completed. The PDA met with the Chairman of the Board in 2013 to discuss the Rebalancing Boards draft proposals on the Section 63 and 64 amendments.

The PDA expressed the view that although the ‘Due Diligence Defence’ would never be able to prove that any pharmacists had acted with ‘Due Diligence’ by showing that they had done all they possibly could to avoid an error from occurring, for in the event of a criminal prosecution this ill-conceived approach would have deprived them of any possibility of mounting a defence. This ill-conceived approach would have deprived them of any possibility of mounting a defence. This ill-conceived plan was eventually withdrawn despite making some considerable progress through parliament.

The latest effort

The Medicines Legislation and Pharmacy Regulation Rebalancing programme board which was convened nearly two years ago has been working on further proposals. The PDA met with the Chairman of the Board in 2014 for two specific reasons, firstly to explain to him exactly what the implications of the Elizabeth Lee case were on labelling offences (Section 85.5) and secondly to discuss the Rebalancing Boards draft proposals on the Section 63 and 64 amendments.

The PDA expressed the view that although after the (Section 85.5) Lee case most pharmacists were more likely to use the long line it still left those pharmacists who were owners exposed and asked that his board addressed that outstanding issue.

In a recent case, the PDA Union was made aware that the Maternity Policy for NHS Commissioning Support Units states that bank holiday leave is not accrued whilst on paid or unpaid maternity leave.

This emerged when a PDA member whose entitlement as laid out in the staff handbook was 27 days annual leave and 8 days ‘General Public Holidays’, sought confirmation that her accrual was 36 days, as she understood it to be her contractual right.

When she was told that public holidays were not accrued she challenged her employer with the support of the PDA Union. She argued that she was being treated less favourably than her colleagues were because of her maternity. Her grievance was rejected and in the employer’s opinion the decision was not discriminatory because:

- Bank holidays should be taken as they fall and as other staff take bank holidays as they fall she is not being treated differently.
- The statutory minimum leave requirements for staff, as the Working Time Directive apply in the UK of 28 days (prorate for part-time) does not differentiate between annual leave and public holidays.
- All NHS staff have a minimum of 27 days leave plus public holidays and therefore with the exception of staff who are on maternity leave for the full ‘leave year’ they would potentially have at least one bank holiday in the year therefore lifting them above the statutory minimum of 28 days.
- The employer conceded that she could accrue one of the public holidays which would take her up to the statutory 28 days but would concede no more.

Counsel has advised the PDAU that there are legal precedents to suggest that public holidays should be included in the contractual entitlement to accrue when on maternity leave. And on the issue of taking bank holidays ‘as they fall’, even if the employer is correct, that the member was required to take them at that point, and did so on the prescribed days during her maternity leave, arguably she was treated less favourably by the employer in such circumstances. Whereas those otherwise at work would get the day off the employee was already off work on maternity leave. For each public holiday she either lost a day of maternity leave or a day of leave for the public holiday.

The member lodged a claim in the Employment Tribunal for unlawful deductions of pay and entitlement and sex discrimination, as she has been disadvantaged whilst on maternity leave.

This is a complex case on the intersect of contract law, domestic statute and European directives. The PDAU expect the claim to be defended vigorously as there will be many employees in the NHS and other organisations that may lodge similar claims seeking these 8 days if this is successful.

Disaster

In 2014 however, it was announced that the MHRA had managed to consolidate section 85.5 of the Act, into the Human Medicines Regulations. The effect of the new wording used now meant that the hard earned interpretation secured in the Elizabeth Lee case was now altogether lost. Currently, all pharmacists are yet again exposed to prosecutions from labelling offences. The PDA has been told that the MHRA would now try and repair the situation and the PDA has asked for a timetable.

In February of 2015, the work of the Rebalancing Committee relating to decriminalisation was released for consultation. That fresh proposals on changes to the law have finally been released is a welcome development. As on previous occasions, the PDA will now be looking objectively at the detail of the proposals and consulting with leading Counsel to establish whether they will provide pharmacists with what they have been waiting for – a meaningful and effective defence to a criminal prosecution in the event that they are involved in the commission of an inadvertent dispensing error.

Members will be provided with an analysis once this assessment is completed.
A New Constitution for the PDAU and new opportunities for you

In 2011 when the PDA Union attained Independent status, it acquired the right to seek to represent members within an organisation to negotiate their terms and conditions collectively. There are certain criteria to meet and hurdles to jump before a union can aspire to exercising these rights because laws have been introduced by successive governments to make union recognition more difficult. However, the PDAU must gear up for the future to take advantage of any developments and to structure its services to meet growing demand for collective bargaining.

A New Union Structure

The Executive has authorised that a new structure, the basis on which the union will be able to expand to meet future needs, be put to the membership by ballot according to the rules.

Currently the union organises itself into national sector Membership Groups.

The sectors represented are: Lucorn (Community Employees), Hospital Employees, Primary Care (Primary Care Specialist and Student & Pre-registration Graduates).

Each group nominates a representative to sit on the National Executive.

The new structure will have a geographical Region as its democratic building block. Each of the four Regions in total shall elect a committee comprising a proportionate balance of members from each sector within the region with the exception of Student & Pre-registration members.

Each Regional Committee will in turn elect a representative to the National Executive. It is important that the pharmacists of tomorrow, students and pre-registration graduates, have a representative voice on the National Executive, so it is proposed that this population will form an elected National Membership Group, which will provide a delegate to the National Executive directly. Alongside these changes the Union will also ensure, that a strong sectional representative process to the National Executive will still exist.

A New Opportunity To Work For The PDA Union

An appointed Regional Union Official will support each Region. The role of the Official will be, to provide the main contact with the Union HQ through the Assistant General Secretary; act as the secretary for the new Regional Committees; predominantly provide or arrange representation for membership who are in dispute with their employers within their respective regions, and drive and support collective representation on NHS and CCG’s staff-side committees.

The size of the Region and the density of the membership will dictate the number of days per month each Regional Official will be required.

PDA is inviting applicants who would like to fulfil this role on a ‘contract for services’ basis (as opposed to an employment contract) for between four to six days per month initially and increasing in time on the expansion of the Union.

The applicant is important and they must have relatively easy access to all parts of the Region they are working in, and be able to travel across the country with little notice.

To find out more go to the union website www.the-pdaunion.org or contact kayleigh.mapstone@the-pda.org

Professor Linda Strand working with the PDA

The definition of Pharmaceutical care is: “A patient centred practice in which the practitioner assumes responsibility for patients medicines related needs and is held accountable for that commitment”.

In short, instead of a pharmacist sending a patient back to their prescriber if a problem with a prescription is identified, under the pharmaceutical care model of practice the pharmacist would take change and make the necessary changes. Such a prospect would require access to patient records, patient registration, a much greater integration of the pharmacist within the primary healthcare team, and a re-engineered and much more clinically driven form of practice.

These principles lie at the very heart of the PDA’s Road Map vision.

One of the architects of this concept of pharmaceutical care is Professor Linda Strand from Minnesota, USA. Her model of care has been operationalised and is already delivering transformational change to more than one million patients in the USA.

Professor Strand is supporting the PDA as it seeks to turn its Road Map vision into a road map vision into an operational model of practice here in the UK.

In the last few months, Linda has spent considerable time at the PDA office and has accompanied PDA officials in meetings with numerous CCG’s in England and with representatives of the Scottish Government as the PDA seeks to support the Scottish Governments “Prescription for Excellence” programme.

Pharmacists who would like to see the Linda Strand lecture at the recent PDA Conference may do so by using the following link: www.the-pda.org/linda-strand

PDA lobbies to remove the impediments to Whistleblowing in Community Pharmacy

Whistleblowing became a significant public interest policy issue for the government after the publication of the Francis Inquiry. This identified that employees had been reporting their concerns about patient safety and critical incidents to management, but that these had not been taken seriously.

Since the end of 2014, NHS bodies have had a statutory duty imposed upon them which now criminalises those NHS employers that fail to exercise their Duty of Candour or fail to act upon any patient safety concerns raised by staff. This change dramatically improves the prospects for healthcare professionals who refer concerns to their employers where they must now take them seriously.

However, these changes do not (as yet) apply to community pharmacy. The PDA has concerns because numerous defence episodes it handles demonstrate how pharmacists are discouraged from raising concerns and whistleblowing because of their poor treatment after raising patient safety issues.

Occasionally, examples of such cases come into the public domain because they have been the subject of Employment Tribunals (see Boots case on page 25).

Consequently, the PDA has serious doubts about whether the culture required to encourage the raising of concerns and in particular to protect whistleblowers currently exists in community pharmacy.

This matter represents a risk to the public. “It is necessary and important to ensure that pharmacists who report concerns about patient safety are protected from any employer retribution,” says Mark Pitt, Director of Defence Services at the PDA.

The government agrees and this was demonstrated recently when the Commons Health Select Committee looked in detail at whistleblowing and concluded that: “the failure to protect whistleblowers remains a ‘stain’ on the reputation of the NHS.”

These are serious concerns and following on from the Francis Inquiry into the Mid Staffs Hospital, Robert Francis QC was tasked by the government to examine the issue of impediments to whistleblowing.

The PDA is keen to focus attention on the problems faced by community pharmacists when seeking to raise patient safety concerns.

Consequently, the PDA has sent a dossier containing the transcript of the recent Boots Employment Tribunal building on other relevant material to Robert Francis QC, and to the Commons Health Select Committee.

Additionally, senior PDA officials have met with the GPhC sharing this material, to ask that they take action to protect patients by supporting pharmacists through a more focussed regulatory framework that removes the impediments created by some employers to whistleblowing in community pharmacy.

Undercover Story – Covert Surveillance

In one recent case a pharmacist working for one of the large multiples found that CCTV cameras had been turned on him without his knowledge or permission.

One day the pharmacist noticed several covert CCTV cameras had been installed in the dispensary. None of the staff knew anything about them and after contacting head office to ask about this, the pharmacist was told they had not been installed by the employer. The PDA member was perplexed and decided to cover the cameras up until it could be established who had installed them and why.

It is important to note that an employer cannot just install covert surveillance to spy on staff and check their levels of work.

The relevant guidance from the Information Commissioners Office states “monitoring through covert means should only be carried out for the detection and prevention of criminal activity or equivalent misconduct” and that consent from the police should then be obtained.

The company subsequently confirmed that it had installed the cameras to covertly observe how the pharmacy was functioning as they had concerns about how quickly the telephone was being answered. The pharmacist was then accused of tampering with the camera and put through a disciplinary process.

This case is still ongoing and the PDA will report on the outcome in the next edition of Insight.
They are asking employers and pharmacy technicians for their opinions but why are they not inviting the opinions of pharmacist employees and locums?

The Government has never been able to explain the rationale behind its thinking satisfactorily, but the plan to operate a pharmacy in the absence of a pharmacist has never been far from its thinking.

Having consistently tried and failed to gain the approval of the GPhC and therefore change the legislation in parliament with the support of the profession since 2006, the Department of Health now plans to have this poisoning challenge managed by the Rebalancing of Medicines Legislation and Pharmacy Regulation programme board. One of its remits is to remove the pharmacy supervision arrangements from statute and transfer them to the pharmacy regulator – the GPhC. Judging by the fact that the government intention has been to enable a pharmacy to operate in the absence of a pharmacist for many years, it is perhaps safe to assume that when this is transferred from statute to regulation, that the GPhC will receive considerable encouragement from the government so as to deliver upon its long standing ambitions. This is of concern to many within the profession.

There is no doubt that the current supervision rules need to be updated, however, the PDA has always maintained that the new rules on supervision and also enhanced roles for pharmacy technicians must seek to make the pharmacist more accessible to the public in the community pharmacy and not less so by dint of not being in the pharmacy at all.

Safety of the public

The PDA has consistently argued that operating a pharmacy in the absence of a pharmacist will impact upon the safety of the public.

current RP regulations so as to enable pharmacists to deliver new services in the community pharmacy since 2006, demonstrated how any ‘permitted’ absences will be widely abused. Currently, in many instances they are not being used for the purposes for which they were intended. In many instances, the ‘two hours permitted absence’ has been used instead by certain pharmacy employers to operate their pharmacies for two hours before the arrival of a pharmacist by requiring their RP to retrospectively sign on upon arrival. They do not pay the pharmacist for this time, as they argue that it is not real work. This demonstrates how a permitted absence designed with the intention of benefiting patients, will simply be used instead to improve profits by reducing operational costs.

Last summer, the head of Pharmacy at the Department of Health (Golé) attended a pharmacy technicians conference and invited them to describe a list of scenarios where they believe the current supervision regulations are affecting the delivery of pharmacy services. These are to be used by the DoH to consider how the supervision arrangements should be changed – perhaps this could be done by allowing pharmacy technicians to undertake more roles.

Since then, the Company Chemists Association has offered their views to DoH officials on scenarios where they believe that remote supervision would be beneficial.

The current supervision rules need updating, but these must make the pharmacist more accessible to the public in the community pharmacy and not less so.

These views are now to be considered by the Rebalancing Programme Board as they consider what changes to the supervision rules should be undertaken. The Programme Board in considering supervision is inviting opinions from pharmacy technicians (many of whom are keen to develop their roles) and also from large multiple employers (some of whom already reduce their operational costs through two hour absence rules). However, the PDA is not aware of them inviting the opinions of those who would be more impacted by any changes; the community employee and locum pharmacists and this is a real concern.

The PDA is keen to ensure that it is not only the views of those who potentially stand to gain through the diminution of the pharmacists role in the pharmacy that are being considered by the programme board.

When the idea of remote supervision was first put out by the government in 2006, it argued that the benefits of pharmacists being able to leave the pharmacy and deliver a range of new and professionally fulfilling services to the public out in the wider community outweighed the risks of not having pharmacists available in the community pharmacy.

Indeed, the government argued (back then) that the pharmacists could develop these new services, then this would likely damage the profession over the long term. However now, nearly a decade later, there are more pharmacists available than anyone dreamed about when this risk vs benefit analysis may have been undertaken in 2006.

Within a couple of years, there’s likely to be several thousands of pharmacists looking for employment. Consequently, the opportunities out in the community can now very easily be delivered by pharmacists, without the need for the pharmacy to be left with no pharmacist on the premises.

There is no longer any need to introduce the risks associated with operating pharmacies without Pharmacists. The question that needs to be asked is why the GPhC’s members will be attempting to introduce risks to the public by continuing to proceed with its policy on remote supervision, when these risks are now entirely unnecessary.

To assist the Rebalancing Programme Board with their work, alongside the examples provided by the Association of Pharmacy Technicians, who at best represent a few hundred members mainly from the hospital sector and also those of the representatives of large employers, it is important that they also receive the views of line employee and locum pharmacists.

The PDA therefore appeals to members to contribute their views as these will be passed at the appropriate board meeting. We ask that members provide us with their views on how they think enabling a pharmacy to operate in the absence of a pharmacist (even for relatively short periods of time), could impact upon patient safety and upon their ability to provide a comprehensive service from a community pharmacy.

It is important that these views are framed as operational workplace impact scenario’s. We provide a few examples of areas that may be affected by a pharmacist absence:

Substantial report itemising the reasons why the current position on P medicines should be maintained and it launched a petition which has thus far secured the support of nearly 6,000 individuals.

Undoubtedly, after all of this activity, pharmacists will be wondering what has happened – has the threat gone away? Or is it still looming?

The answer is that the threat has not gone away and this is very much still ‘on the GPhC radar’. However, the GPhC will now hold a consultation on the matter – something that it previously appeared not inclined to do. This consultation, when it comes however, will not just be about P-Meds on self-selection, it will also be part of the much wider consultation that deals with the outcomes of the work of the Rebalancing of Medicines Legislation and Pharmacy Regulation programme board (Decriminalisation, remote supervision and skill mix). This may eventually occur in 2016, and only then if the new government pursues the same policies.

The PDA will therefore publish its substantive P-Meds report and will advise pharmacists as to how to engage further with the PDA’s petition and the GPhC’s consultation when it is the most appropriate time.

To sign the P-Meds petition go to www.the-pda.org
To strike off or not to strike off?

Currently, the Pharmacy Regulator – the GPhC issues guidance to the disciplinary committees as to what kind of sanctions they should impose upon pharmacists appearing in front of them. At the end of 2014, the GPhC instigated a consultation to review the scope of the areas for which guidance is issued and the sanctions that should be considered.

The areas upon which feedback was sought included Dishonesty, Sexual Misconduct, Duty of Candour, Raising Concerns and Aggravating and Mitigating factors.

The PDA defends pharmacists in the majority of the GPhC’s disciplinary hearings, it experiences all of these matters and has offered detailed responses, a short report follows.

Dishonesty

The PDA believes the GPhC has struggled with how it handles dishonesty for some time. Dishonesty covers a very wide range of matters and yet the committees appeared not to be taking account of the degree of dishonesty, nor were they keen to take account of any mitigating factors. Pharmacists where in many cases simply being struck off for all forms of dishonesty. This is the equivalent of executing a thief who this is for the petty theft of an apple or for grand larceny. In particular, the PDA is concerned that the committees have struggled with how it handles dishonesty. This is the kind of environment where such professionalism can flourish. What is happening instead is that there is an ever growing regulatory focus upon the actions of pharmacists on the one hand but there is a lack of regulation of non-pharmacist employers on the other. This is creating an impossible NO WIN situation for pharmacists and patients alike. For pharmacists, the current approach by the GPhC represents increasing risks to their patients, their continued registration, their livelihoods and their mental health. This is a matter of the utmost strategic importance and it is a matter that the PDA has urged the GPhC to consider very seriously.

The PDA has warned the GPhC that unless there is a culture and an environment in which employers genuinely address concerns raised by pharmacists, then the GPhC’s proposals will provide no benefits to patients whatever other than to produce a record of unaddressed concerns. Nothing contained in the GPhC’s proposal to deal with raising concerns appears to be linked to placing a duty upon employers to resolve the issues being raised. This is pivotal to resolving the problem.

The Francis Report found that healthcare staff often attempt to comply with this duty, but that it can be suppressed by the management and the organisational culture of the employer. No matter how well managed, without the support of the employer, the Duty of Candour becomes that much more difficult for pharmacists to exercise.

As NHS bodies, hospitals now have a statutory duty which criminalises those that fail to notify errors that cause harm to patients. This does not yet apply to community pharmacy. Employer organisations and non-regulated line managers have a significant role to play in the delivery of healthcare services and often have an involvement when something goes wrong, therefore they surely must also have a responsibility to participate in the Duty of Candour, but currently, this is not the case in community pharmacy. This discrepancy poses a significant threat to patient safety especially if pharmacists are line managed by non-regulated personnel.

The PDA experiences situations where employee pharmacists and locums are told by their employer not to make any contact with patients nor to make any inquiries in the event of a dispensing error. They are told to stay out of the process because the employer will make contact with the patient. Often however, when such contact is made by Head Office, it is done very belatedly and in a style which does not focus upon a Duty of Candour, but upon mitigating a civil claim in compensation. We believe that this is because the employer fears that in allowing the pharmacist to make contact with the patient, the pharmacist may damage the employer’s brand.

Or alternatively, that in talking with the patient or the GP, the pharmacist may draw attention to flawed systems and processes within the employers’ organisation. This could cause more compensation to be paid to that patient in the event of a civil liability claim being pursued or worse still (for an employer) that the employer ends up being referred to a regulator.

In such situations, pharmacists are in a conflict between their professional Duty of Candour and their employer’s instruction not to make contact with the patient or other.

The PDA has recommended that non-pharmacists such as hospital or area managers who are deemed to should be regulated by the GPhC and should have a Duty of Candour placed upon them as this would deal with a major cause of dilution of the public interest in pharmacy.

Whilst the PDA fully supports the Duty of Candour in principle, it believes that the current pharmacist focussed approach being taken by the GPhC will not get to the root of the problem.

Raising Concerns

The GPhC wants committees to take very seriously a finding that a pharmacist has failed to raise concerns about the workplace.

The PDA argues that an environment and culture must first exist in pharmacy where individuals are supported by employers in raising concerns about standards of care and risks to patients. Currently, in many cases, such a supportive environment does not exist especially in community pharmacy where there is an overtly commercial environment. The PDA member experience shows that not only are pharmacists not being supported in raising concerns, but they actually face substantial barriers to discourage them from doing so, such as:

- Being benefited by line managers for not being team players because they refuse to operate in an unsafe pharmacy environment.
- Being downgraded in salary reviews after raising safely serious concerns.
- Having their promotional prospects adversely affected after raising concerns.
- Having their capability unfairly questioned after raising concerns.

Some pharmacy employers see a pharmacist who is prepared to work in woe fully inadequate conditions as someone having a positive employee attribute and they consider this a valuable employee characteristic.

Even if pharmacists do make a stand, the concerns that they raise are often disputed by more senior managers and are not resolved.

Recently, a damning verdict written by a judge after the PDA successfully supported a member at an Employment Tribunal against Boots shone a light upon similar issues (See page 25).

If pharmacists raise concerns then this can lead to career limiting consequences, especially at a time when they can be easily replaced. Unsurprisingly, many pharmacists who have families to look after feel they have little alternative other than to muddle on as best as they can.
PDA SEEKS TO SECURE A SECOND PHARMACIST IN EVERY PHARMACY

The Pharmacy Contract Global Sum is shrinking in real terms. Employers are seeking ways to control their salary bills by reducing the number of hours for pharmacist cover and then either reinvesting it in support staff or making savings. Furthermore, there is fear in many quarters that Government is promulgating ‘skill-mix’ strategies, and encouraging the deskilling of the dispensing operation simply to justify the reduced income that pharmacy can expect despite the increase in volume, year on year.

To suggest that the skill-mix can be better utilised to release more pharmacist time, is true to an extent, but in the PDA’s view it is an over-simplification and fails to recognise the pharmacist’s contribution to patient safety.

Support staff play a crucial role as part of the healthcare team in a pharmacy but their skills and training must not be over-exaggerated and they should not be used as substitutes for pharmacists.

The PDA, is therefore seeking to promote a case that;

-improved patient safety, improved health outcomes and increased economic benefits can be achieved by employing more pharmacists in pharmacies, not less.

The suggestions therefore that each pharmacy should have more than one pharmacist available to oversee the dispensing operation, and more dedicated resource to deal with OTC advice and Public Health counselling will no doubt be met with dissain in some quarters, but before they object, the objectors should consider the following;

- The availability of ‘Summary Care’ records require the application of highly developed clinical skills that only a pharmacist can perform. If their use is applied diligently, this will have enormous benefits for patients, but it will put the pharmacist under more scrutiny should they miss a critical drug reaction. Taking short-cuts because of time pressures will be little mitigation if the pharmacist could have saved a life but failed to.

- Pharmacies have historically been the only group of health care professionals freely accessible to the public through the community pharmacy network yet they are spending less, not more, face-to-face time with patients because of excessive workloads. Too much of this activity is now delegated to support staff with less expertise. Patients are deriving reduced value from these interactions and should expect more. Pharmacists with specific expertise could prevent damage to health caused through the excessive and inappropriate taking of OTC medication, and at the same time be the filter for patients with conditions more worthy of an in-depth investigation by their GP.

- Pharmacists can remove significant pressure from the financially strapped NHS if utilised properly and integrated into the health system coherently through the effective treatment of minor ailments. A role that can only be delivered effectively if pharmacists are more able to engage in patient facing interactions.

- The process of dispensing and the means of distribution (delivery drivers as an example) is becoming less, not more, safe. In the PDA’s experience, the number of serious incidents and deaths caused by dispensing and delivery errors is at an all time high.

- The excessive outflow of pharmacy graduates already point to supply outstripping demand in an industry increasingly being controlled by non-pharmacists seeking to maximise profitability by reducing head count and taking short-cuts which damage patient safety.

PDA Project Group

The PDA has set up a project group to identify the benefits of funding more than one pharmacist per pharmacy. Its remit is to

1. Identify missed opportunities for patient care due to there being insufficient pharmacist time in community pharmacies to perform a more comprehensive role.
2. To seek out the evidence and identify further research needed.
3. To establish the cost and health outcome benefits that may be derived by increasing the number of pharmacists in community pharmacies.

The PDA made proposals in its Pharmacy Road Map for Community Pharmacy to embrace a strategic career pathway. Making a case for a dispensary based and a patient facing pharmacist is an opportunity to create that structure and to stake a claim for specialist roles in traditional areas of practice which will demonstrate the advantageous health outcomes to be gained in using more pharmacists more appropriately in a community setting.

This project is an extension of the PDA’s mission to enhance current and develop new roles for its members.

Join your colleagues. Be part of a membership of over 46,000 pharmacists, pre-registration trainees and student members.

Our professional, legal, ethical and good practice guidance materials support you in your day-to-day practice.

Continue to develop your knowledge through our quick reference guides and online support alerts.

Read The Pharmaceutical Journal and find out about career opportunities and developments. The learning section will help you meet your CPD training needs.

Record your professional development in your online Faculty portfolio. This can be used to help you submit your CPD record, and will support Continuing Fitness to Practice.

Join today at www.rpharms.com/pda

www.the-pda.org

Two heads are better than one
In a large proportion of the encounters where the Summary Care Record was accessed potential harm was avoided, with a significant proportion of these being episodes where a prescribing error was identified and prevented. One member told the PDA that having accessed the SCR to make a relatively innocuous inquiry, he identified and was able to prevent a potentially life threatening allergic reaction. Access to the SCR has clearly improved patient safety.

Currently, the SCR is also being used in situations where a vital piece of the jigsaw is missing. Little surprise then that in the vast majority of encounters where the SCR was accessed, pharmacists subsequently did not need to send the patients back to the GP as they were able to resolve the issue within the pharmacy. At its most basic level, SCR use by pharmacists would reduce the pressure on GPs and this is before other, more sophisticated nuances of SCR use are exploited.

The trial will be evaluated once it has concluded later in the year. Nonetheless it is already possible to see how the use of the SCR could transform community pharmacy practice and provide pharmacists with just the tool that they have needed to be able to do justice to the vitaly important task of the performing the clinical check. In recent years, as advances in medicines manufacture were made, original pack dispensing has become the norm and the traditional ‘mixing the medicines’ role has become obsolete.

Today, the medicines assembly function is being seen by the government as a technical and not a professional role and it has even argued that a pharmacist need not be on the premises as such technical activities can be undertaken by technicians and be supervised remotely by pharmacists.

However, the PDA has consistently argued that in addition to the vital public health and the accessible advice roles performed by pharmacists in a community pharmacy, a vital professional role of the pharmacist which is irreplaceable is the clinical check on the prescription. Importantly, such a check can establish whether the prescribed medicines are safe or appropriate for the patient, or whether there has been a prescribing error.

The pharmacist may detect harmful interactions with other prescribed medicines or those purchased over the counter, or identify dosages that may not be optimal and change them. Such a clinical check can also establish whether a patient understands how best to use their medicines. It involves an interaction with the patient, with their carer and often with the GP. In the most complex situations, this interaction is undertaken at prescription receipt and when the patient returns for their medicine.

In a hospital setting, the interaction with patients is undertaken on the wards, in a community pharmacy however, this role is performed in the pharmacy where the prescription is presented by the pharmacist and where the public come for the advice.

The demographic changes in Society has seen many more elderly patients being cared for by the NHS and this trend is set to increase dramatically. Increasingly, pharmacists are seeing prescriptions being presented for patients on polypharmacy regimes and suffering with multiple conditions.

This places a much greater burden upon the vital clinical check performed by pharmacists. Currently, this valuable check is under threat; the sheer volume of prescriptions being dispensed and the reduction of staffing levels by employers have resulted in pharmacists often working flat out just to get the medicines dispensed and leaving little time to consider the potential need for checking.

The biggest hurdle, in terms of being able to undertake a quality clinical check, is that there has been the lack of any access to patient information other than the pharmacy PMR. This is in stark contrast to hospital pharmacy where patients drug charts can usually be found on the wards.

With pharmacists being able to access the patients Summary Care Record, this may be set to change. Pharmacists could transform their current role, by concentrating their efforts in an area which is neither technical nor mechanical but one which is entirely professional, requiring the specialist input of a pharmacist.

The good news is that community pharmacists may not be too far away from seeing such a possibility become reality.

**The Summary Care Record trial**

Since 2014, 125 community pharmacies throughout the UK have been invited to participate in a trial whereby they were given access to the Summary Care Record (SCR) of patients. The purpose of this trial was to establish three things:

1. Whether use of the SCR improved patient safety
2. What would the optimal operational model would look like
3. Whether the use of the SCR in community pharmacy could be of benefit to relieving the stress on other parts of the NHS

The 125 sample size is small, but despite this and even though the trial has not yet concluded, according to those pharmacists involved, already some very positive evidence is being generated. A more comprehensive reliance upon the SCR could allow pharmacists to get on top of the medicines waste issue, to tackle ADR’s and even help to avoid unnecessary hospital admissions.

Furthermore, if used as part of a service which was integrated with other members of the primary healthcare team, it could create much more capacity for GPs enabling them to see more patients with acute conditions because they could refer out conditions with longer term conditions to pharmacists. To drive such benefits, pharmacists would need to be routinely accessing the SCR with the majority of patient presentations and seeking out opportunities to optimise medicines use.

Undoubtedly, this would take much longer than does the current dispensing service and would necessitate a significant re-engineering of community pharmacy practice. One consequence would be the need to re-evaluate skill mix in one pharmacy requiring the presence of more clinical expertise and probably more than one pharmacist in the pharmacy (see feature on page 12).
The unintended consequence of providing such a desirable, convenient service is that it appeases consumer expectation and acts to accentuate their belief that medicines are no more than a normal item of commerce, and are to be treated much the same as a pizza delivery. The PDA has been applied but that the driver had not delivered the correction label to the address indicated on the label. Fortunately there was no harm to the patient, and with the involvement of the PDA the allegations into the pharmacist’s conduct were readily accountable by his employer as the RP were dropped. This particular incident had occurred over a Christmas period and at a time when the usual delivery driver had left and had not been permanently replaced, which meant that a driver had been ‘loaned’ by another branch.

Public holidays are notoriously more difficult periods and pharmacies are typically stretched to the limit. Being mindful of this and having a heightened awareness could be enough to minimise the risk of incidents arising.

On this occasion the pharmacist was rightfullyabsolved of responsibility, but the PDA are involved with cases on a daily basis, where pharmacists are disciplined for being in breach of SOPs, and not conducting a check on the bag label which is applied prior to delivery could easily fall under that description.

WHAT ARE THE LEARNING POINTS?

Many pharmacies are heavily burdened by the preparation of monitored dosage supply and delivery systems with insufficient levels of staffing, which means that labels are often generated many days or weeks in advance.

The PDA has long advised pharmacists not to be party to any pre-labeling which inevitably increases the risk of errors. However, if a pharmacist believes that they have no option, or is ‘parachuted in’ to a process that is already in train, there needs to be a system in place that allows for a clear audit trail for the complete chain of supply.

Ask yourself when was the last time you sat down to look at the SOPs for such prescriptions and are they even applicable to your pharmacy? When was the last time you discussed these with your delivery driver? Are there provisions for what to do if patients are unable to sign for medication? Do patients know they are expected to sign for receipt? What does the driver do if no one is in? Do you see the delivery record once it is returned? Where is it kept?

Many patients who are having medication delivered are also having the same medication administered to them by carers employed to do so, and who have a duty of care in making basic checks but who are often untrained. Every opportunity must be taken for a collaborative approach between GPs, pharmacists, carers and patients.

Do not make an assumption that because you are informed that you have made an error, that you are responsible for it. Take the appropriate responsibility when you have all the facts. Obtain the evidence for your self and do not necessarily rely on those that have made the allegation until you are sure. It is often very difficult to piece together exactly what has happened after a significant event has occurred, which is why PDA always advises pharmacists to be proactive about gathering together every source of evidence and information that is available as soon as possible after the event becomes apparent.

It can be very difficult for locum pharmacists to obtain information about an incident that they have little involvement in remedying and they are often told by the employer that certain information has to be withheld from a confidentiality/governance perspective.

➔ If you are involved in an incident, from both a professional and a civil liability viewpoint, you are entitled to know everything about that incident. You have a professional responsibility to investigate where you went wrong and why, so as you can apply risk management strategies in future.

➔ You are personally liable should a claim for compensation be made against you and you should be expected to collect the evidence in the event that there is one. You have the right, as the person who is being made accountable for an error and who is bound by the same duty of confidentiality as the employer, to see the relevant information – which may include the patient details. You should not take ‘no’ for an answer when you request such detail and the superintendent pharmacist should be contacted if there are any difficulties.

In addition to PDA experiences, there was story that made the headlines last year (Mail Online, 8th January 2014) about a toddler who was thought to have ingested medication that had been posted through the letter box. A 21 month old child was caught by his father retrieving Trajenta tablets from the door mat. The Trajenta had been delivered to an incorrect address and the child was about to ingest them.

Fortunately it seems that the child did not actually swallow any of the antidiabetic medication and no harm was caused. It was a straightforward delivery error, which could have and should have been averted.

At least the pizza delivery boy wouldn’t deliver the items unless someone is there to take them in.

"Pizza makes me think that anything is possible" said Henry Rollins, musician, writer, journalist, publisher, actor, television and radio host.
In 2012, the PDA instigated a series of conferences around the UK to focus on the problems looming on the horizon regarding the over production of pharmacy graduates.

This enabled the PDA to develop a two track approach to the problem of oversupply of pharmacists;

• Controlling the numbers of undergraduates so as to reduce the over-supply on the one hand
• Developing new roles for pharmacists so as to increase the demand for pharmacists on the other

The detailed outcome can be found at www.the-pda.org/seven-point-plan

Ultimately, this activity and garnering the involvement of other bodies in pharmacy led to the research which was undertaken by the Centre for Workforce Intelligence. This showed what everyone already knew, that a crisis in pharmacy student numbers needed to be urgently addressed.

With the backing of a coalition of pharmacy bodies a consultation was undertaken by the Higher Education Funding Council (HEFCE) and a recommendation was put to the University Minister to introduce a cap on pharmacy student numbers. The previous Universities Minister appeared sympathetic and it looked like the requested changes would take place.

A new Universities Minister was appointed and to everyone’s surprise, he concluded that despite all these recommendations, no cap should be applied.

A new campaign has been instigated and in the last three months several PDA officials and PDA members have lobbied key members of parliament.

On November 27th 2014 a question was put to the new Universities Minister in the House of Commons and he provided his response in December.

“Ask the Secretary of State for Business, Innovation and Skills, for what reasons the cap on the number of dental and medical students has not been extended to cover pharmacy students.”

“Pharmacy students are funded in the same way as chemistry, biology and other science subjects which will not be subject to a student number control at HEFCE funded institutions in 2015/16. Medicine and dentistry attract a much larger amount of HEFCE grant funding than science subjects like pharmacy. Therefore it would not be appropriate to cap pharmacy student numbers.” Greg Clark

The PDA is keen to keep up the pressure and seeks members help by asking them to lobby their own local MP. There are many arguments that members could use and MPs are currently in listening mode due to the forthcoming General Election. We provide some of the arguments that may be of use;

1. Universities teaching Medicine and Dentistry do attract a higher HEFCE grant than is the case for each pharmacy graduate, but the Pharmacy Pre-reg year attracts an additional £230,000 per graduate of government funding (DoH).

2. Many pharmacy courses are being provided to undergraduates as part of a broader health faculty where pharmacy, medical and other healthcare undergraduates attend many of their lectures together.

3. Pharmacy is not a science subject in the same way as is Chemistry or Biology, the vast majority of pharmacy graduates work in healthcare roles and in patient facing situations.

4. The Centre for Workforce Intelligence has estimated that if the current approach continues, there will be thousands of pharmacy graduates who will never qualify as pharmacists because there are not enough pre-registration training posts. This is not only a waste of tax payers money, but this surplus will bring the Higher Education system into disrepute.

5. Rarely have all of the pharmacy bodies been so aligned, they all agree that pharmacy student numbers should be capped. This is also the position of the Department of Health.

6. One of the most important roles of a pharmacist is to ensure that an employer’s profit driven demands do not stand in the way of patient safety. The tension between these two, often conflicting forces, has hitherto been managed by pharmacists often in the face of intense pressure from employers. Already the emerging oversupply is challenging this healthy tension because some unsuspicious employers are taking advantage of the ease with which they can get replacements that will do their bidding. This represents a diminution in the safety of the public.

7. Unemployment in pharmacy will make it increasingly difficult to attract high calibre undergraduates to Pharmacy Schools. This will damage the patient interest since the complex challenges placed by medicines upon Society generally means that pharmacy needs to employ high calibre individuals if it is to meet these challenges.

The PDA will continue to press for changes to the current policy and will seek to exploit the manifesto pledges being made by the various political parties.
Hang ‘Em High....er

Are the GPhC getting tougher?

BACKGROUND

Readers will be depressingly familiar with the well trodden route to the GPhC Fitness to Practise Committees that pharmacists accused of Medicines Use Review (MUR) irregularities, face. The journey starts with an employee pharmacist, usually working for one of the big multiples, who is unable to cope with management demands to meet MUR targets. The pharmacist either falls behind with completing the necessary paperwork or reports figures for completed MURs that cannot be subsequently verified. The company disciplinary machinery finds the pharmacist guilty of gross misconduct and they are summarily dismissed. The employee makes a complaint to the GPhC who commence their own investigation.

At the hearing, the pharmacist will face allegations of acting dishonestly due to fraudulent MUR claims being made and sometimes because of initial denials of responsibility. For all healthcare professionals, a finding of dishonesty lies at the top end of the spectrum of misconduct and they are summarily dismissed. The company disciplinary machinery finds the pharmacist guilty of gross misconduct and they are summarily dismissed. The employee makes a complaint to the GPhC who commence their own investigation.

In trying to explain his misconduct, this pharmacist stated that the pressure to meet targets was relentless via email, telephone calls and visits. The pressure, he said, took the form of area managers ringing him on a daily basis, asking how many MURs he had done and from area managers who maintained league tables, using these to embarrass people. He said there were continuous emails describing the number of MURs done in each store in the area and threats that he would be put on a Performance Improvement Plan and even face dismissal if targets were not met.

A large proportion of pharmacists working in community pharmacy will be familiar with the sort of pressure described above. However the Committee did not believe him after hearing from a senior company manager who gave evidence that the picture painted by the pharmacist was simply not correct. The manager said that the company approach was to examine with the member of staff concerned those performance issues are, identify causes and problems, consider support and training to ease the pressure and even consider increasing staff. The Committee chose to believe the manager and discounted any undue pressure as a factor. Unfortunately the pharmacist only conceded late in the day that he had claimed for MURs that he had not in fact done. The Committee felt that this was an admission that should have been made much earlier on and saw this as evidence of failing to take responsibility and lacking insight.

LESSONS TO BE LEARNED

Judging by recent developments, the GPhC are taking a tougher line with pharmacists involved in fraudulent MUR claims. Committees seem unwilling to hold employers to account for their part in creating a culture where pharmacists feel they have no option but to resort to misconduct to meet unreasonable targets to keep their jobs. Had this pharmacist contacted the PDA at an earlier stage, we believe that he would have avoided being removed from the register. The PDA has an effective and tested strategy for dealing with MUR pressure and pharmacists should seek prompt advice. As the Chairman says, the GPhC will have no sympathy for those that do not raise concerns.

A MESSAGE TO THE PROFESSION

On the issue of MUR pressure the Chairman gave a stark message to the profession before directing the removal of the pharmacist:

“The exercise of professional integrity requires sometimes that a pharmacist must stand up and be counted. If pressures of work prevent the proper discharge of professional responsibilities, the professional owes a duty to his patients and to his profession to voice that concern, uncomfortable though it might be to do so. A professional does not engage in dishonesty, despite personal provocation or the consequences for himself and even for his continued employment in a particular appointment”

Whistle blowing has been a hot topic in the press for a while now. This is driven partly by the aftermath of the public inquiry into the Mid Staffordshire NHS Foundation Trust conducted by Robert Francis QC and partly from a number of scandals affecting care homes. Whistle blowing, in the context of pharmacy, is usually defined as disclosing information (a protected disclosure) in good faith usually to an employer, which in the reasonable belief of the worker tends to show that the health and safety of any individual has been, is being or is likely to be endangered. For example raising concerns about staffing levels, the working environment, an unsafe workflow or indeed any other matter which may adversely impact upon patient safety can all fall into the category of whistle blowing in pharmacy. There are other types of protected disclosure, but in this article we focus on common issues faced by pharmacists at work.

Community pharmacy employers may have thought they had escaped scrutiny in this area, but a recent case brought by a pharmacist against Boots (See page 29) shines a spotlight on one particularly poor piece of legislation and highlights the poor treatment of one whistleblower who worked for the largest pharmacy multiple in the UK.

This article describes how pharmacists should respond if they are concerned about patient safety at work. Done for the right reasons, whistle blowing is a commendable act and for employees at least, there is a robust legal framework in place to protect individuals from being disadvantaged as a result. Whistle blowing can be a catalyst for improving patient safety and the PDA believe that this piece of legislation is under used in community pharmacy and one that is widely misunderstood by employers.

To protect whistle blowers, employers have legal safeguards from being subjected to any detriment by any act, or any deliberate failure to act, by the employer on the ground that a protected disclosure has been made. In community pharmacy examples of detriments could include being excluded for closing the pharmacy, being put onto a performance improvement plan unfairly or being downgraded at salary review as a consequence of whistle blowing. Other examples include being overlooked for promotion or being moved out of the pharmacy.

Pharmacists may be concerned that there does need to be a clear link between the whistle blowing act and being subjected to a detriment. This is not necessarily the case as the burden of proof shifts to the employer. In practical terms once a tribunal accepts that a protected disclosure has been made and a detriment suffered, it is down to the employer to prove that the worker was not subjected to the detriment on the grounds of making a protected disclosure. Nor does the detriment need to be a major one; what is important is that any complaint to an Employment Tribunal must be made within three months of the detriment itself. Other piece of good news is that a claim can be brought whilst the pharmacist remains in employment; there is no need to resign and further statutory protection kicks in once a complaint is made to a tribunal.

Pharmacists can remain in their job after making a whistle blowing claim and the GPhC are currently dealing with such a case in another pharmacy multiple.

KEY POINTS TO REMEMBER

1. Pharmacists are encouraged and expected to raise patient safety concerns by the GPhC and the profession
2. Concerns should be raised in writing and set out what the health & safety issues are, as well as all the consequences for patient safety
3. Keep a written record of discussions and interactions with company managers
4. Raise a grievance which attracts the right of union representation
5. The time limits for bringing a claim are very strict and normally this must be done within 3 months of suffering a detriment
6. Take advice from the PDA Union at an early stage
7. Consider reporting concerns to the GPhC if your employer is not taking them seriously
Flexible Pensions – What Pharmacists Need to Know

From April 2015, a lot of the restrictions on what you can do with your pension pots will be lifted. Widely regarded as a positive step, everyone will soon have a lot more freedom to do as they please come retirement.

It doesn’t matter whether this will affect you tomorrow or in 40 years, what is really important is to understand the implications and how you can best take advantage of the situation.

In order to help, here’s a summary for PDA members on what’s changed, how this affects your pension and the most common risks involved.

An Independent Financial Adviser’s opinion

As an advocate for objective-based financial planning, I’ve welcomed these changes. More freedom makes it that much easier to build a financial plan around what matters to you.

Still, this is my opinion as a professional financial adviser. I spend my day studying the financial world in order to make sense of it, so I’m also aware that complete freedom of choice might be overwhelming to the majority of people. Particularly those who don’t spend as much time looking at spreadsheets, graphs and indexes as I do.

The traditional restrictions

Pension funds have traditionally been used to buy an annuity at retirement. This way, a saver could secure an income for the rest of their life. Wealthier savers were permitted to leave the pension fund invested and draw an income from the growth – an option called “income drawdown”. However, limits did apply.

To be eligible for Flexible Drawdown, you currently have to meet a minimum level of ‘secure income’ before drawing an income directly from your pension.

Secure income is defined as:

• State pension and social security benefits
• Occupational pensions
• Private pension annuities

The minimum level used to be £20,000, which is why the majority of people had to purchase a private pension annuity. However, this threshold was reduced to £12,000 for the current (2014/15) tax year and will be removed entirely from April 2015.

This means you can use Flexible Drawdown on a fund of any size, without needing to arrange a secure income.

What this means for retirees

Income (or Flexible) Drawdown isn’t anything new. However, the requirement to provide a ‘secure income’ meant these were only accessible to those with larger pension funds.

While this means a lot of pharmacists would be eligible, they would still have to use a sizeable portion of their personal pension fund to purchase a secure income.

From April 2015, you will have access to your entire pension fund, with no restrictions, from the age of 55. Although, there will be tax implications to bear in mind.

The Wealethiest You’ll Ever Be

From the age of 55, you will probably have direct access to more cash than you ever have in your life time. You’ll probably be the wealthiest you’ve ever been. Or ever will be, for that matter.

Once you retire, your wealth is going to diminish over time. The traditional restrictions were designed to ensure you didn’t run out of money. Now that this is gone, this responsibility is yours.

Outlining your retirement fund is a very real risk.

What about Final Salary Schemes?

Final Salary schemes are exempt from the rule change. At your retirement date, you will begin to receive your benefits over time with the option of a cash lump sum.

However, it is likely there will be ways to transfer benefits to a personal pension and cash that in.

In the majority of cases, it would not be beneficial to sacrifice the long term benefits of a Final Salary Pension for a lump sum in the short term. Final Salary Pensions offers generous benefits that would be hard to find elsewhere.

If you are being advised to transfer, make sure the source of advice is a pension transfer specialist.

It’s daunting

The flexibility offered is certainly daunting. A lot of my clients who are approaching retirement had always expected to purchase an annuity. They were comfortable with this.

Now, being asked to consider other options is quite intimidating.

However, I expect to see a host of innovative new products emerging in the coming years.

And, while annuities still play a big part in catering for retirement, it will definitely pay to consider your options.

As the appointed provider of financial advice for the PDA, we’re here to help.

For retirement advice or to book a review, call 01823 250750 or visit www.lloydwhyte.com.

Author Profile

Daniel James Bourne is Director of Client Services at Lloyd & Whyte, who are the appointed independent financial advisers of the PDA.

For advice on any of the issues raised in this article, contact Lloyd & Whyte on 01823 250750 or through their website at www.lloydwhyte.com.

Regulations

Lloyd & Whyte (Financial Services) Ltd are authorised and regulated by the Financial Conduct Authority. Calls may be recorded for use in quality management, training and customer support.
Undergraduate FtP under scrutiny?

By Joy Wingfield
Professor of Pharmacy Law and Ethics

Most readers of this article will not be undergraduates, but imagine for a moment that you still are. Imagine… in your wilder youth, you got involved in an arson attempt at the local school resulting in a “police caution”. You didn’t declare it when your MPharm course but now it has come to light. Will you be able to continue your course? Will you be able to get on the register at the end of your training?

There are no guaranteed answers to these questions. The PDA handles cases where late disclosure of a caution has resulted in the student being removed from the course; in another, no action was taken. Much depends on the context of the offence, the level of insight shown by a student and what are known as “aggravating” or “mitigating” factors.

Examples of undergraduate behaviours that might attract University FTP hearings

- Criminal conviction, caution or similar relating to theft, fraud, possession of illegal substances
- Drug or alcohol misuse, including driving with excess alcohol
- Aggressive, violent or threatening behaviour
- Failure to cooperate or attitude or behaviour such as lack of commitment to study, work, or other responsibilities
- Management or control of administrative tasks
- Cheating or plagiarising – cheating or passing all other works as one’s own
- Dishonesty or fraud, including dishonestly outside the professional role
- Unprofessional behaviour or attitudes such as bullying, harassment, rudeness
- Health concerns and lack of insight or management of those concerns

Courses for medical and nursing students have long included fitness to practise (FTP) requirements. Following the Shipman inquiry about a doctor who had deliberately caused the death of hundreds of his patients, all health professions were required to bring in similar FTP processes. So, in 2009 a student code of conduct and associated FTP procedures were introduced to pharmacy undergraduates.

The student code of conduct

In essence, the code requires pharmacy students to conduct themselves professionally as soon as they enter their degree course. This applies both on and off campus. The code is not explicit about requiring undergraduates to proactively report misdemeanours but it is, however, perhaps implied in phrases such as “tell your university if there is anything that could impair your ability to study.”

Fitness to practise procedures in Schools of Pharmacy

The GPhC plays no part at all in student fitness to practise procedures. It does, however, require every School of Pharmacy to have such processes in place (as part of course accreditation) and to use them where needed.

The GPhC also issues guidance on the scope and operation of such processes, most importantly requiring that the school “must tell students that poor behaviour or health before or during their course may affect their ability to enter a pharmacist pre-registration training or to register as a pharmacist.” Importantly, the guidance clarifies that students cannot be “considered, and not as yet as “a pharmacist”. Most schools now introduce workshops into the first few weeks of the course to make sure that this requirement is well understood, often, these are supported by the PDA.

What might bring you before the school’s FTP panel?

The student code of conduct and the FTP guidance are available on the GPhC website. To illustrate the threshold that undergraduates might cross, the guidance lists some useful questions:

- Has a student’s behaviour harmed patients or put patients at risk of harm?
- Has a student shown a deliberate or reckless disregard of professional responsibilities towards patients, other students, staff or others?
- Is a student’s health or impairment compromising the safety of patients, themselves, other students, staff or others?
- When acting in a professional or academic-related activity, has a student behaved fraudulently, or in a way designed to mislead or harm others?
- Has a student failed to abide by the code of conduct for pharmacy students?

Five years on

At a recent session at the RPS annual conference for pharmacy lecturers, it was clear that some trends were emerging. A mere handful of cases - mainly criminal - were considered by the GPhC prior to pre-registration or full registration. The GPhC will review the code of conduct and may add in more about professionalism, the need to understand and learn from one’s mistakes, a duty of candour and how the code is applied across a five year integrated course.

The GPhC expressed concern about the unexplained lack of consistency at some of the Schools of Pharmacy: the need to avoid conflicts of interest and the requirement to follow the principles of natural justice. All undergraduates, for example, must be entitled to see all the evidence and to be accompanied by the representative of their choice, and according to the PDA, this does not always happen.

For the Schools of Pharmacy and the staff who are involved in implementing the procedures, sitting in judgement on student behaviour is no easy task. Most recognise that now is a good time to compare notes for students and academics to look at consistency and proportionality in outcomes and to share best practice.

Boots in court after losing whistle-blowing case

An Employment Tribunal recently considered a claim by a PDA Union member who was forced to resign after raising patient safety issues that Boots failed to take seriously. The Tribunal identified a culture of failures and heavily criticised senior managers. Names have been changed for the purposes of this article.

Background

Peter was a member of the PDA Union and brought a claim against Boots for suffering a detriment as a consequence of whistleblowing and constructive dismissal. His complaint related to being placed on a Performance Improvement Plan (PIP) by Debbie, a non-pharmacist store manager, as a result of making a protected disclosure (see page 21) relating to the reckless and avoidant behaviour of one of the pharmacy’s staff, Peter then threatened Peter’s job security and subjected him to a character assassination, as well as threatening to discipline him for gross misconduct on questionable grounds.

Peter complained to the pharmacy superintendent but his grievance was delegitated to a Regional HR manager. Peter’s complaint was not taken seriously and investigations were of poor quality, with managers deliberately avoiding key questions being asked during the grievance about Debbie’s honesty and integrity. The last straw for Peter was being criticised by Debbie when he closed the pharmacy for an hour on the grounds of patient safety and a suggestion that he meet informally with the principle pharmacist to call her evidence.

Debbie did not attend the hearing and her absence was described as “unusual” by the court. No explanation was given; the PDA Union believes the company knew how damaging she would be to its case and decided not to call her evidence.

The judge found that Debbie had pressurised staff to falsify company records about the completion of staff training and described her actions as “underhand” and “inherently dishonest”. The tribunal were scathing about internal investigations and had reservations about the process used by Boots to confirm the competence of its staff.

Debbie’s behaviour towards Peter was described by the Tribunal panel as unacceptable and entirely inappropriate. The panel found that company investigations should have been dealt with far more speedily and managers were treating the complaint with a lack of seriousness.

It went on to say that investigations contained glaring omissions and did not deal properly with key issues. The appeal manager was not “fully engaged” with the allegation that Debbie was dishonest and he did not challenge her about key points of the grievance.

Peter won his case and the Tribunal concluded that he had been unfairly dismissed after the behaviour of both Debbie and Boots had destroyed the employment relationship. They also agreed that Peter had suffered a detriment because he blew the whistle after closing the pharmacy on patient safety grounds.

Tribunal hearing

Peter was not given the opportunity to articulate criticism in such forthright terms and clear from the judgement that the panel were unhappy with the conduct of senior managers and the application of company processes. Boots tried to portray Peter as a pharmacist about whom it had genuine performance concerns and that his complaint was merely a reaction to these.

The Tribunal saw through that argument and found he was a genuine whistle-blower and a capable pharmacist who was concerned about patient safety and who had resigned as a result of the poor treatment he was subjected to by both the manager and the company.

Peter’s success was down to following carefully the advice of PDA Union lawyers, expert representation and good record keeping; this case was a textbook example of how a Union can secure the right outcome for a pharmacy whistle-blower in a tricky area of law.

The PDA member is currently waiting for his financial compensation to be decided by the court.

Conclusion

The judgement shines a spotlight on the difficulties that pharmacists can face when reporting serious patient safety concerns. It is rare for a Tribunal to articulate criticism in such forthright terms and clear from the judgement that the panel were unhappy with the conduct of senior managers and the application of company processes.

See news section on page 7 for further developments relevant to this case.
The PDA Union is aware that many of its members work overtime on a regular basis – whether there is an obligation to do so in their contract or not. Few are aware that, as a result of a recent decision by an Employment Appeal Tribunal (EAT), that their extra hours could now have an impact upon their accrued holiday pay.

Since 2004, guaranteed overtime (where the employer is obliged by the contract to offer and pay for agreed overtime) must have been included within a calculation of holiday pay for an employee. An (EAT) has recently ruled that non-guaranteed overtime (where there is no obligation by the employer to offer overtime, but if they do then the worker is obliged by the contract to work it) also needs to be taken into consideration when calculating holiday pay entitlement. This Judgment may therefore effect pharmacists who work non-guaranteed overtime on a regular or consistent basis.

The Employment Appeals Tribunal Judgment

The EAT judged that overtime payments should form part of an employee’s holiday pay calculation where the overtime was regularly worked. It determined that if there is a settled pattern of working, the overtime payments forms part of a week’s pay for the employee. If there is no settled pattern of working, yet the employee still regularly works overtime, the average weekly overtime over a 12-week period is established to calculate the accrued holiday pay.

In this case, the Claimant, Mr Fulton argued that his holiday pay should reflect his overtime pay as well as his basic wages. He worked a 35-hour week, plus overtime when necessary, which meant that he regularly worked up to nine hours each day and occasionally up to 12 hours to provide cover. He felt his holiday pay should reflect the actual pay he received rather than his basic salary alone, although overtime work was voluntary according to his employer. Voluntary overtime is where the employer asks staff to work overtime and the worker is free to turn down the request as there is no contractual obligation on either side to offer or refuse overtime. Mr Fulton’s holiday pay had previously only taken account of his basic pay. The Tribunal however ruled that the hours he worked over and above his contractual hours were ‘intrinsically linked’ to the performance of his role, and commented that it was irrelevant whether the overtime was voluntary or not, the point was, that Mr Fulton regularly worked overtime.

The question of voluntary overtime has not been previously considered by any recent judgments and so there is currently no definitive case law to suggest that voluntary overtime needs to be taken into account when calculating holiday pay. However, in this case the ET determined that it did not need to distinguish.

This ruling means that workers should now have their normal non-guaranteed overtime taken into account when their annual leave is being calculated. The EAT determined that this was the correct interpretation of the law even if overtime was not guaranteed in the contract by the employer.

Extra accrued holiday pay capped at 4 weeks worth of overtime pay

For the purposes of calculating any accrued holiday pay, a week’s pay will now have to be calculated on an employee’s actual income, including overtime, if that employee regularly works over and above their contracted hours. However, only the 4 weeks’ annual leave entitlement under the original Working Time Directive apply to this Judgment, rather than the full 5.6 weeks’ leave provided by the Regulations as they operate in the UK. Any subsequent claims for back pay following this ruling therefore are only for the European minimum entitlement of 4 weeks holiday per year so any extra holiday entitlement you receive will be capped at 4 weeks worth of overtime pay.

For example if a pharmacist has a holiday entitlement of 6 weeks, for the first 4 weeks only of that entitlement, s/he should now be paid extra money over and above their normal contractual pay, accrued as holiday pay as a result of their normal working pattern (which by definition includes overtime). The Tribunal has not directed how and when this money should be paid. It is a very complicated calculation and the employer therefore has discretion whether to pay it at the time holiday is taken, spread out over the months/quarters or in a lump sum at the end of the year.

As part of its Judgment, The Employment Appeal Tribunal also decided how far back in time workers can claim they have been underpaid by their employer. Ordinarily, if your employer owes you money you can bring a claim in the County Court within a 6 year period as a breach of contract, however the Government, mindful of the financial impact on business, acted quickly to limit the period and on 8 January 2015 brought into effect the Deduction from Wages (Limitation) Regulations 2014.

These Regulations amend the Employment Rights Act 1996 to introduce a maximum two year backstop to most unlawful deduction of wages claims covering holiday pay relating to overtime, commission, bonuses and some other fee arrangements. This backstop will apply to claims presented after 1 July 2015, so between 1 July and 1st January there is a transition period during which time unlawful deduction of wages claims will have no limit in how far back they can go subject there being no break in the series of deductions.

The Regulations will not affect deduction of wages claims for other types of remuneration, for example statutory maternity pay or statutory sick pay. The PDA Union believes that as case law develops, it won’t be too long before a challenge is made that regular overtime payments should be taken into account for the purposes of contributory pension schemes.

Going forward, the Union expects to see employers tightening up the wording in contracts and policies in regards to overtime, holiday entitlement and calculation of holiday pay.

For now however it is clear that many workers will be able to accrue extra holiday pay particularly pharmacists for whom working overtime is considered by employers as a normal part of the job.

PDA Union Advice to Members

The PDA Union has advised members who are paid for regular overtime commitments on whether or not they are entitled to receive extra accrued holiday pay. Although advice is available on an individual basis the best way to approach the matter is as follows.

• Members should check their contractual obligation in respect of overtime by looking at their employment contract to ascertain whether they are obliged to work overtime.

• If this is not resolved then members could lodge a claim in the EAT. Please be aware that a claim to an ET must be lodged within 3 months of the last day of the last time any part of the holiday entitlement was taken.

• If a member is not obliged to work overtime but is regularly expected or pressured to do so (for example lunchtime cover), there still may be a claim. The Judgment referred to suggests that this is the case although there is currently no definitive case law on this point so it will have to be clarified by the EAT at some point in the future.

• If members are asked to agree any new contracts altering overtime conditions proceed with caution and preferably contact the PDA for advice to protect their position.
WHY JOIN US?
Every day our members tell us...

If ever there was a time for pharmacists to have their rights protected – then that time is now!

✓ More than 4,000 cases handled last year alone
✓ More than £1,000,000 compensation secured from employers who have treated pharmacists unfairly or illegally
✓ £500,000 worth of Legal Defence Costs Insurance
✓ £5,000,000 worth of Professional Indemnity Insurance
✓ Union membership option available

Visit our website: www.the-pda.org
Call us: 0121 694 7000

OVER 23,000 MEMBERS
Have you joined yet?

I very much appreciate your guidance and advice at a time which was very stressful to myself
LOCUM

I'm not sure what I would have done without the help of the PDA
HOSPITAL EMPLOYEE

I'm really thankful for the help I received throughout the investigation
REGULATORY COMPLAINT

The service provided by the PDA is truly invaluable and I would not have got through the last year without the PDA
CORONER’S INQUEST

The outcome would be very different if the PDA rep wasn’t there!
Thank you for saving my job!
COMMUNITY EMPLOYEE